TargetBeta
MAP4K1
mitogen-activated protein kinase kinase kinase kinase 1 · also HPK1 · MAP4K family (GCK-I subfamily)
1 program in company-led studies act on MAP4K1, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Hpk1 Inhibitor PRJ1-3024rule | Zhuhai Yufan Biotechnologies | phase 2 | 33 running | – | NCIt |
Conditions their studies are in
- Melanoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 15, 2027Hpk1 Inhibitor PRJ1-3024 · Zhuhai Yufan Biotechnologies · phase 2 · NCT05315167
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.